u Verigen Inc., of Hopkinton, Mass., reported that in on-going clinicalstudies of its PASSHIV(R)-1 with 16 HIV-1 infected patients, the drugshowed it is "well tolerated" and may have "significant" clinical,antiviral and immunological effects. PASSHIV(R)-1 is animmunoglobulin G therapeutic derived from HIV-1 lysate immunizedpigs. Verigen said mounting evidence has indicated the therapy is not acure because it does not remove HIV-1 from infected cells.u Less than a week after the FDA approved Albunex, MolecularBiosystems has received regulatory approval to market its ultrasoundcontrast imaging agent in the U.K. The San Diego-based MolecularBiosystems is marketing Albunex in Europe and the U.K. under anagreement with Norway-based Hafslund Nycomed AS.u Genta Jago Technologies B.V., of Basel, Switzerland, has filed aninvestigational new drug application with the FDA for a twice-dailyoral controlled release form of acyclovir for treatment of genital herpesand other herpetic infections. Acyclovir is the generic name forZovirax, which is on the market, but is administered five times a dayfor herpes outbreaks.
(c) 1997 American Health Consultants. All rights reserved.